Nowadays, the incidence rate of hyperlipidemia caused by overwork, irregular life, eating too much meat and fish is increasing year by year. How to control and lower blood lipids has become a common concern for everyone. Currently, taking statin based lipid-lowering drugs is the most commonly used method for lowering blood lipids. However, what should be done when statins have poor efficacy or adverse reactions? Listen to the suggestions from the clinical pharmacy Department of Pharmacy Department of Beijing Electric Power Hospital to find Zhikun clinical pharmacist. Scientific research has shown that statins can treat cholesterol or lead to "escape" phenomena. Some cholesterol in our body is ingested, called "exogenous cholesterol", accounting for about 1/4 of the total; It is synthesized by the liver and is called "endogenous cholesterol", accounting for about 3/4. Under normal circumstances, what comes from outside and what comes from within the body will maintain dynamic balance. So we traced back to the source, stating that statins can lower cholesterol, which is the pathway that inhibits cholesterol synthesis. This is the big end. However, it has no control effect on absorption. Moreover, statin drugs not only inhibit liver cholesterol synthesis, but also feedback to increase intestinal absorption of cholesterol, and some patients may experience the phenomenon of "escape" of statin effects. These two drugs combined to attack cholesterol comprehensively, so Ezetimibe, an intestinal cholesterol absorption inhibitor, jumped into the research field of clinical pharmacy. The principle behind it is that Yizhemai Bu inhibits the absorption of cholesterol by the intestine into the human body. When statin based lipid-lowering drugs have poor efficacy, they can assist in reducing blood lipid levels. Let's explore how Yizhemai cloth exerts this magical effect. Yizhemai Bu has a "unique technique" in inhibiting cholesterol absorption. Cholesterol is absorbed through the brush like edge of small intestinal mucosal cells, and Ezemab acts on the brush like edge of small intestinal mucosal cells to inhibit the absorption of cholesterol by the small intestinal mucosa, which can reduce absorption by about 20%. Therefore, the combination of statins and ezetimibe can complement each other's mechanisms and block both internal and external pathways of cholesterol sources. Good safety tolerance and compatibility with commonly used cardiovascular drugs. Ezetimib has good safety and tolerance. The distribution of Yizhemai Bu in the body is mainly limited to the small intestine and liver, with extremely low drug exposure in the circulatory system and no systemic accumulation effect. And it is not metabolized through the CYP450 enzyme system, so it does not interact with most drugs, especially commonly used drugs for cardiovascular diseases, such as statins, amiodarone, digoxin, warfarin, clopidogrel, etc. The adverse reactions of Yizhemai Bu are mild and transient. The common adverse reactions are digestive system abnormalities, such as abdominal pain, diarrhea, flatulence, elevated transaminase, and fatigue and headache in some patients. Ezumab can be used alone, but when used alone, its lipid-lowering intensity is relatively low. It is often used in combination with statins to increase the effect of reducing density lipoprotein cholesterol (LDL-C), reduce the dosage of statins, and reduce the occurrence of adverse reactions. However, it should be noted that, compared with the use of statins alone, there are more incidents of transaminase level increase in ezetimibe combined with statins, and regular monitoring of biochemical indicators is recommended. The treatment scope is wide, but these three types of patients are prohibited